SG
SGMT.US Sagimet Biosciences Inc. Series A Common Stock
- Market cap
- USD 709M
- P/E
- -
- P/B
- 3.04x
- ROE
- -24.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SGMT.US undervalued?
Graham numberThe Graham number of Sagimet Biosciences Inc. Series A Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sagimet Biosciences Inc. Series A Common Stock fundamental analysis
No fundamental analysis for Sagimet Biosciences Inc. Series A Common Stock yet.
Sagimet Biosciences Inc. Series A Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also deve…
Full company profileSagimet Biosciences Inc. Series A Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sagimet Biosciences Inc. Series A Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -88.0K | -124K | -134K | -130K | 2.00M | - | - | - |
| Operating Income | -14.2M | -11.4M | -23.7M | -31.1M | -30.7M | -54.5M | -56.9M | -65.5M |
| EBITDA | -14.2M | -11.3M | -23.7M | -31.1M | -27.9M | -45.6M | -51.0M | -58.3M |
| Net Income | -14.3M | -11.4M | -24.4M | -30.5M | -27.9M | -45.6M | -51.0M | -58.3M |
| EPS | -0.64 | -0.51 | -1.10 | -1.38 | -1.53 | -1.45 | -1.58 | -0.94 |
| Balance Sheet | ||||||||
| Total Assets | 11.2M | 69.0M | 59.0M | 33.0M | 96.7M | 160M | 116M | 282M |
| Total Liabilities | 136M | 205M | 217M | 220M | 5.65M | 4.45M | 5.10M | 39.9M |
| Shareholders' Equity | -125M | -136M | -158M | -187M | 91.1M | 156M | 111M | 242M |
| Cash & Short-term Investments | 10.2M | 68.7M | 56.7M | 32.3M | 94.9M | 151M | 113M | 236M |
| Total Debt | 341K | 210K | 348K | 211K | 65.0K | 78.0K | 78.0K | 2.02M |
| Cash Flow | ||||||||
| Operating Cash Flow | -10.6M | -10.4M | -21.7M | -24.5M | -23.8M | -42.4M | -45.7M | -41.9M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -10.6M | -10.4M | -21.7M | -24.5M | -23.8M | -42.4M | -45.7M | -41.9M |
| Ratios | ||||||||
| ROE | - | - | - | - | -30.6% | -29.2% | -45.8% | -24.1% |
| ROA | -127.8% | -16.5% | -41.4% | -92.3% | -28.8% | -28.4% | -43.8% | -20.7% |
| Net Profit Margin | - | - | - | - | -1,393.8% | - | - | - |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sagimet Biosciences Inc. Series A Common Stock dividends
Sagimet Biosciences Inc. Series A Common Stock has not paid dividends in the last 7 fiscal years.
Who owns Sagimet Biosciences Inc. Series A Common Stock
- Insiders 2.79%
- Institutions 97.21%
- Public & others 0.00%
- Shares outstanding 71.4M
- Free float 61.8M
Top funds holding SGMT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Kaufmann Small Cap A | 2.08M | 2.94% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.86M | 2.62% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.49M | 2.10% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.36M | 1.91% | +2.69% | Oct 2026 |
| abrdn Life Sciences Investors | 1.22M | 1.73% | +5.20% | Oct 2026 |
| BGF World Healthscience A2 | 658K | 0.93% | 0.00% | Jul 2026 |
| Fidelity Small Cap Index | 643K | 0.91% | 0.00% | Aug 2026 |
| BlackRock Health Sciences Opps Inv A | 585K | 0.83% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann R | 541K | 0.76% | 0.00% | Sep 2026 |
| abrdn Healthcare Investors | 532K | 0.75% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 448K | 0.63% | -0.19% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 440K | 0.62% | -0.38% | Oct 2026 |
| Federated Hermes MDT Small Cap Core IS | 431K | 0.61% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 342K | 0.48% | +1.35% | Sep 2026 |
| BlackRock Health Sciences Term Trust | 301K | 0.42% | +36.70% | Jun 2026 |
| Fidelity Extended Market Index | 290K | 0.41% | +1.73% | Sep 2026 |
| iShares Micro-Cap ETF | 178K | 0.25% | 0.00% | Oct 2026 |
| Bridgeway Ultra-Small Company | 166K | 0.23% | -31.94% | Jun 2026 |
| Dimensional US Small Cap ETF | 145K | 0.20% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 143K | 0.20% | 0.00% | Sep 2026 |
Top institutions holding SGMT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 6.58M | 9.27% | +722.03% | Jun 2026 |
| Balyasny Asset Management LLC | 3.63M | 5.11% | 0.00% | Jun 2026 |
| Woodline Partners LP | 3.00M | 4.23% | +199.78% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.93M | 4.13% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.57M | 3.62% | +133.53% | Jun 2026 |
| Bvf Inc | 2.50M | 3.53% | 0.00% | Jun 2026 |
| Caligan Partners LP | 2.50M | 3.53% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 2.50M | 3.52% | +187.77% | Jun 2026 |
| Federated Hermes Inc | 2.09M | 2.94% | +267,085.02% | Jun 2026 |
| Great Point Partners LLC | 2.03M | 2.86% | 0.00% | Jun 2026 |
| State Street Corp | 2.00M | 2.81% | +1,449.13% | Jun 2026 |
| Saturn V Capital Management LLC | 1.48M | 2.09% | 0.00% | Jun 2026 |
| Aberdeen Group PLC | 1.48M | 2.08% | +74.01% | Sep 2026 |
| Geode Capital Management, LLC | 1.44M | 2.04% | +366.53% | Jun 2026 |
| Blue Owl Capital Holdings LP | 1.26M | 1.78% | +277.55% | Jun 2026 |
| Baker Bros Advisors LP | 953K | 1.34% | 0.00% | Jun 2026 |
| Millennium Management LLC | 937K | 1.32% | +8.67% | Jun 2026 |
| The Goldman Sachs Group Inc | 759K | 1.07% | +348.48% | Jun 2026 |
| Hillhouse Capital Advisors, Ltd. | 725K | 1.02% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 581K | 0.82% | 0.00% | Jun 2026 |
Sagimet Biosciences Inc. Series A Common Stock company profile
- Company name
- Sagimet Biosciences Inc. Series A Common Stock
- Ticker
- SGMT.US
- Exchange
- USA Stocks
- Listed since
- Jul 14, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- 155 Bovet Road, San Mateo, CA, United States, 94402
- Phone
- 650 561 8600
- Website
- sagimet.com
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc. Series A Common Stock management
8- Mr. David A. HappelCEO, President & Director · born 1962
- Ms. Elizabeth Rozek Esq., J.D.Chief Legal & Administrative Officer · born 1972
- Mr. Urs Greber Ph.D.Co-Founder
- Dr. Lucas Pelkmans Ph.D.Co-Founder
- Mr. Thierry ChaucheCFO & Principal Accounting Officer · born 1976
- Dr. Marie O'Farrell Ph.D.Chief Scientific Officer
- Mr. Robert D'UrsoSenior Vice President of New Products
- Dr. Andreas Grauer M.D.Chief Medical Officer · born 1961